Durect Stock Discussion

$Durect (DRRX.US)$
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT (DRRX) has sold its ALZET® osmotic pumps product line to Lafayette Instrument Co. for $17.5 million. The transaction includes certain assets and liabilities associated with the ALZET line.
DURECT used the proceeds to pay off its remaining obligations under the Oxford Finance term loan.
The company states this sale strengthens its cash position and extends runway t...

$Durect (DRRX.US)$
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design
- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint;topline results expected within two years of trial initiation
 - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b tr...

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$  Phase 2
$Supernus Pharmaceuticals (SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$  Phase 2a
$MorphoSys (MOR.US)$  Phase 2
$Nuvation Bio (NUVB.US)$  Phase 2
$ALX Oncology (ALXO.US)$  Phase 2
$BioXcel Therapeutics (BTAI.US)$  Phase 2
$Purple Biotech (PPBT.US)$  Phase 2
$Arcus Biosciences (RCUS.US)$  Phase 2
$Medicenna Therapeutics (MDNAF.US)$  Phase 2b
$Affimed NV (AFMD.US)$  Phase 2
$Barinthus Biotherapeutics (BRNS.US)$  Phase 2b...

$Durect (DRRX.US)$ Reuters· 1 min ago
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis